Economic Burden of Parkinson's and Atypical Parkinsonism in the United States

Read full text Summarise with VIRAT
Authors: L. Kirsch
Cited by: 0

Summary

No summary yet. VIRAT can read this paper and write a plain-language summary of its aim, methods, key findings and limitations.

Summarise with VIRAT Free to try with your Science Catalogs account.

Abstract

Why we did this study: Parkinson’s disease (PD) and atypical parkinsonisms (AP) are progressive neurodegenrerative disorders which impose a substantial socioeconomic burden on patients, families, and healthcare systems due to the long-term care, loss of productivity, and extensive costs associated with disease progression. This study seeks to understand and quantify these costs by estimating the current (2024) and future economic burden of PD and AP in the United States. What we did: We calculated per-person estimates of (1) direct medical costs, (2) indirect costs, and (3) non-medical costs and medical exspenses not covered by insurance related to a person’s PD and AP care. Example direct medical costs are doctor visits, hospitalizations, and prescription drugs; indirect costs include productivity loss and earnings loss related to premature death; non-medical costs include household expenditures for therapeutic goods and activities. The direct and indirect costs specifically attributable to PD/AP were determined by comparing costs for people with PD/AP against a demographically-similar comparison group. We multiplied these per-person estimates by an estimated prevalence of PD and AP in the U.S. to calculate the total economic burden. Our calculations are based on government-provided data on healthcare utilization (e.g., Medicare and Medicaid claims, CDC, CMS survey data and U.S. Census data), private medical insurer data, and direct surveys of people living with PD/AP and their care partners.

Fields of Study & Subjects

Parkinson's Disease Mechanisms and Treatments Health Systems Economic Evaluations Quality of Life Economic and Financial Impacts of Cancer

Publication details

Journal / source
Zenodo (CERN European Organization for Nuclear Research)
Publication date
17 February 2026
Language
EN